Word: dr
(lookup in dictionary)
(lookup stats)
Dates: during 1990-1999
Sort By: most recent first
(reverse)
Laser technology is changing so fast that even veterans of the field can hardly keep up. When he developed the first argon lasers back in the 1970s, says cosmetic-laser pioneer Dr. Richard Fitzpatrick, "we had one laser for everything. Now I have 25 lasers." Soon, he predicts, lasers will reach beneath the skin without causing any surface wound at all, to rejuvenate the skin's structure and reverse sun damage. In five years we may even have home lasers for facials. Fitzpatrick's partner, cosmetic-laser surgeon Mitch Goldman, predicts that in 10 years, you'll be able...
Tracey McNamara had never seen anything like it. In July, dead crows began turning up by the dozens at New York City's Bronx Zoo. By August, McNamara, the zoo's staff pathologist, had collected carcasses of 40 birds. Meanwhile Dr. Deborah Asnis, an infectious-disease specialist at Flushing Hospital in Queens, reported the admission of two elderly patients with muscle weakness, fever and confusion...
Nichols' story is remarkable. He not only fought for the drug's development in the face of total disinterest by drugmakers and mainstream cancer scientists but may also have opened the door to a whole new family of cancer drugs. Says Dr. Francis Giardiello, chief of gastroenterology at Johns Hopkins: "He spurred them to look into this a lot deeper and a lot faster than they would have otherwise. He has a proud legacy." He may also posthumously save the life...
...began reading the medical literature and calling scientists. Eventually he talked to Dr. Randall Burt, now the chief of gastroenterology at the University of Utah. Coincidentally, Burt had just heard University of Colorado surgeon William Waddell tell a scientific meeting that he had seen an aspirin-like arthritis drug called sulindac (Merck) almost miraculously melt away colon polyps. The finding was anecdotal, observed in only a few patients, but it was just what Nichols wanted to hear...
Although bringing a new drug to market can be time-consuming (up to 15 years) and costly ($500 million), Nichols was undaunted. In 1989 he started his own pharmaceutical company, Cell Pathways, with Dr. Rifat Pamukcu--the lone physician at the University of Chicago who had supported his decision to forgo surgery--as chief scientific officer. At first, Nichols used his own money, then he turned to friends, and finally he sold off shares to venture capitalists, eventually raising $81.5 million but leaving him with only an insignificant interest in Cell Pathways. Getting rich was never his goal...